Truist raised the firm’s price target on Boston Scientific (BSX) to $130 from $129 and keeps a Buy rating on the shares. The company reported a solid Q3 earnings beat, with accelerating Watchman growth seen as the standout, the analyst tells investors in a research note. Truist adds it is confident that Boston Scientific can still deliver upside to a now higher guidance, the firm added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target raised to $130 from $125 at Morgan Stanley
- Boston Scientific: Strong Growth Trajectory and Attractive Valuation Drive Buy Rating
- Boston Scientific price target raised to $140 from $135 at UBS
- Boston Scientific price target raised to $125 from $124 at Wells Fargo
- Boston Scientific’s Strong Performance and Promising Outlook Justifies Buy Rating